Escolar Documentos
Profissional Documentos
Cultura Documentos
RSS
Assine o nosso feed RSS
Autores: Dr. Antonio Claudio do Amaral Baruzzi, Dra. Anna Maria Andrei, Dr. Marcos Knobel, Dr. Elias Knobel
Não se recomenda mais o uso de rotina de macromoléculas como a CPK, DHL, TGO
e TGP pela inaceitável falta de acurácia diagnóstica. Além do mais, para a American
Heart Association e a Sociedade Européia de Cardiologia, até mesmo a CKMB
somente deve ser realizada se as troponinas não estiverem disponíveis (Tabela 5).
Figura 4.
(Clique na imgaem para ampliá-la)
Nível sérico de marcadores de necrose miocárdica x tempo após início dos sintomas. Pico A: liberação precoce
de mioglobina. Pico B: troponina. Pico C: CKMB. Pico D: elevação de troponina com CKMB normal. Modificado
de National Academy of Clinical Biochemistry, Washington, DC, 1999.
Figura 5.
(Clique na imgaem para ampliá-la)
Marcadores de necrose miocárdica no IAM–CST. Os marcadores fundamentais para avaliar pacientes com IAM-
CST são as troponinas e a CKMB. A linha horizontal define o limite superior da referência do marcador. Essa
referência representa o percentil 99 de um grupo-controle de referência sem IAM-CST. As cinéticas de liberação
de CKMB e troponinas de pacientes que não receberam reperfusão são mostradas nas linhas sólidas verde e
vermelha, como múltiplos da referência. Note que em pacientes submetidos à reperfusão (linhas verde e
vermelha tracejadas) os marcadores são detectados mais brevemente, têm um pico mais alto e caem mais
rapidamente resultando em uma menor área abaixo da curva e um infarto de menor tamanho. Modificado de
Alpert et al. Am Coll Cardiol 36:959, 2000 e Wu et al Clin Chem 45:1104, 1999.
• sintomas isquêmicos
Artigo de Revisão
Infarto agudo do miocárdio: fisiopatologia,
diagnóstico e tratamento
Acute myocardial infarction: pathophysiology, diagnosis, and treatment
Introdução
Fisiopatologia
Diagnóstico
Tratamento
Medidas gerais
Medidas específicas
Bibliografia
1. American Heart Association: 1999 Heart and Stroke Statistical Update.
Dallas, American Heart Association, 1998.
2. Braunwald E. Evolution of the management of acute myocardial infarction:
a 20th century saga. Lancet 1998; 352: 1771-4.
3. Antman EM, Braunwald E. Acute myocardial infarction. In: Braunwald E,
Zipes DP, Libby P editors. Heart Disease: a textbook of cardiovascular
medicine. 6th edition. Philadelphia, W.B. Saunders Company; 2001. p.1114-
219.
4. Davies MJ. The pathophysiology of acute coronary syndromes. Heart 2000;
83: 361-6.
5. Lima VC. Síndromes isquêmicas agudas. Arq Bras Cardiol 1999; 72: 109-
23.
6. Libby P. Current concepts of the pathogenesis of the acute coronary
syndromes. Circulation 2001; 104: 365-72.
7. Verri J, Fuster V. Mecanismos das síndromes isquêmicas agudas e da
progressão da aterosclerose coronária. Arq Bras Cardiol 1997; 68: 461-7.
8. Pedoe-Tunstal H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM,
Pajak A. Myocardial infarction and coronary deaths in the World Health
Organization MONICA Project. Circulation 1994; 90: 583-612.
9. Lee TH, Juarez G, Cook EF, Weisberg MC, Rouan GW, Brand DA, et al.
Ruling out acute myocardial infarction. A prospective multicenter validation of
a 12-hour strategy for patients of low risk. N Engl J Med 1991; 324: 1239-46.
10. Rude RE, Poole K, Muller JE, Turi Z, Rutherford J, Parker C, et al.
Electrocardiographic and clinical criteria for recognition of acute myocardial
infarction based on analysis of 3697 patients. Am J Cardiol 1983; 52: 936-42.
11. Myocardial infarction redifinned-A consensus document of the Joint
European Society of Cardiology/American College of Cardiology Committee for
the Redifinition of Myocardial Infarction. Eur Heart J 2000; 21: 1502-13.
12. Del Carlo CH, O'Connor CM. Cardiac troponins in congestive heart failure.
Am Heart J 1999; 138: 646-53.
13. National Heart Attack Alert Program Coordinating Committee-60 Minutes
to Treatment Working Group. Emergency department: rapid identification and
treatment of patients with acute myocardial infarction. Ann Emerg Med 1994;
23: 311-29.
14. Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratza LF, et al.
1999 Update: ACC/AHA guidelines for the management of patients with acute
myocardial infarction: executive summary and recommendations. Circulation
1999; 100: 1016-30.
15. II Diretriz da Sociedade Brasileira de Cardiologia para o tratamento do
infarto agudo do miocárdio. Arq Bras Cardiol 2000; 74(supl II): 7-18.
16. ISIS-2 (Second International Study of Infarct Survival) Collaboration
Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or
neither among 17187 cases of acute myocardial infarction. Lancet 1988; II:
349-60.
17. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wave-front
phenomenon of isquemic death I. Myocardial infarct size vs duration of
coronary occlusion in dogs. Circulation 1977; 56: 786-94.
18. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, et
al. Prevelence of total coronary occlusion during the early hours of transmural
myocardial infarction. N Engl Med J 1980; 303: 897-902.
19. Sadanandan S, Hochman JS. Early reperfusion, late reperfusion, and the
open artery hypothesis: na overview. Prog Cardiovasc Dis 2000; 42: 397-404.
20. ISIS-4: A randomised factorial trial assessing early oral captopril, oral
mononitrate and intravenous magnesium sulphate in 58.050 patients with
suspected acute myocardial infarction. Lancet 1995; 345-669-85.
21. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and
after myocardial infarction: an overview of the randomized trials. Prog
Cardiovasc Dis 1985; 27: 335-71.
22. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy
on the infarcted left ventricle of the rat. Circ Res 1985; 57: 84-95.
23. Zornoff LAM, Matsubara BB, Matsubara LS, Tornero MTT, Spadaro J. Efeito
do lisinopril na isquemia experimental em ratos. Influência do tamanho do
infarto. Arq Bras Cardiol 1999; 73: 359-65.
24. Zornoff LAM, Matsubara BB, Matsubara LS, Paiva SAR, Spadaro J. Early
rather than delayed administration of lisinopril protects the heart after
myocardial infarction in rats. Basic Res Cardiol 2000; 95: 208-14.
25. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, et al. Long-term
ACE-inhibitor therapy in patients with heart failure or left ventricular
dysfunction: an systematic overview of data from individual patients. Lancet
2000; 355: 1575-81.
26. ACE inhibitor myocardial infarction collaborative group. Indications for ACE
inhibitors in the early treatment of acute myocardial infarction: systematic
overview of individual data from 100,000 patients in randomized trials.
Circulation 1998; 97:2202-12.
27. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H.
Effectsof the early administration of enalapril on mortality in patients with
acute myocardial infarction: results of the Cooperative New Scandinavian
Enalapril Survival Study II (CONSENSUS II). N Engl Med J 1992; 327: 678-84.
28. Jugdutt BI. Role of nitrates after acute myocardial infarct. Am J Cardiol
1992; 70:82B-7B.
29. GISSI-III: Effects of lisinopril and transdermal glyceril trinitrate simply and
together in 6 week mortality and ventricular function after acute myocardial
infarction. Gruppo Italiano per lo Studio della Supravivenza nell'Infarto
Myocardico. Lancet 1994: 343: 1115-22.